Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025JCO Oncology Practice

Role of a Designated Pharmacist in Reducing Adverse Drug Reaction Rates and Preventing Potential Medication Errors in Hematology-Oncology: A Randomized Controlled Trial

View Full Paper
Ask AI
Bookmark
Share

Authors

AAAreen Khateeb AlabbasiMGManfred S. GreenSBShuli Brammli‐Greenberg

Discussion

Loading...

Member takes

Overview

Randomized controlled trial shows reduced adverse drug reactions and enhanced medication error detection in oncology patients.

Key Points

  • The intervention group had significantly lower rates of adverse drug reactions, suggesting pharmacist involvement is beneficial.
  • Results indicated an age-adjusted hazard ratio of 0.38 for at least one adverse drug reaction among those receiving pharmacist intervention.
  • The methods employed a randomized controlled trial design to assess the pharmacist's impact on reducing medication errors.
  • These findings highlight the importance of integrating pharmacists into hematology-oncology clinics for improved patient safety.

Cite This Study

Alabbasi et al. (2025) studied this question.

synapsesocial.com/papers/68c1a78854b1d3bfb60e13f1https://doi.org/10.1200/op-25-00158
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Economic evaluation of a designated oncology pharmacist in hemato-oncology outpatient care: A randomized clinical trial.2026
  2. 2Association of Pharmacist Interventions with Adverse Drug Events and Potential Adverse Drug Events2024
  3. 3Reducing drug-related problems in hospitalized pediatric cancer patients through clinical pharmacist interventions: An interventional study from Turkey2025 · 2 citations
  4. 4Evaluation of clinical pharmacy services in patients receiving antithrombotic treatment in a randomized controlled trial2025
  5. 5Evaluation of clinical pharmacy services in patients receiving antithrombotic treatment in a randomized controlled trial2025